U.S. Markets Post Fourth Straight Weekly Loss Amid Middle East Escalation 
Asian Currencies Rebound as Dollar Weakens, BOJ Holds Rates 
Oil Prices Slide as U.S. Eyes Iranian Supply Relief Amid Middle East Tensions 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
U.S. Stock Futures Steady as Wall Street Retreats on Oil Volatility and Fed Rate Outlook 
Asian Markets Tumble as BOJ Holds Rates, Oil Surges Past $110 
Saudi Arabia Warns Oil Prices Could Surge Past $180 a Barrel Amid U.S.-Israel-Iran Conflict 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem 
Elliott Investment Management Takes Activist Stake in Align Technology 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Genel Energy Reports FY25 Net Loss Below Fears, EBITDAX Beats Forecasts 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Volkswagen CEO Urges Germany to Adopt China's Industrial Discipline Amid Major Restructuring 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
